Analysts at Citi have revised their price target for Cabaletta Bio (CABA, Financial), cutting it to $13 from a previous $17, while maintaining a Buy rating on the stock. The adjustment follows the company’s latest quarterly report. Cabaletta Bio has secured the FDA's agreement on the design of a pivotal trial for its rese-cel treatment in myositis. The company now predictssubmitting its application for full market approval by 2027. Citi's analysts note that with this regulatory milestone, Cabaletta Bio is positioned as a potential frontrunner in the myositis CAR-T therapy market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Cabaletta Bio Inc (CABA, Financial) is $16.22 with a high estimate of $28.00 and a low estimate of $3.00. The average target implies an upside of 798.74% from the current price of $1.81. More detailed estimate data can be found on the Cabaletta Bio Inc (CABA) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Cabaletta Bio Inc's (CABA, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
